Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Nct04512345 refractory anaerobic bacterial infections tinidazole?

What is NCT04512345 testing, and is tinidazole part of it?

NCT04512345 is a clinical trial identifier. Tinidazole is an oral nitroimidazole antibiotic used against anaerobic bacteria, but the details of whether tinidazole is included in NCT04512345 depend on the specific trial protocol (intervention(s), dosing, and study arms). The provided prompt doesn’t include the trial’s intervention information, so I can’t confirm from your text alone whether tinidazole is used for refractory anaerobic bacterial infections in that study.

If you share the trial’s brief summary or the “Interventions” section text (or the link), I can tell you exactly whether tinidazole is included and what role it plays.

Would tinidazole treat “refractory” anaerobic bacterial infections?

Tinidazole can treat infections caused by susceptible anaerobic bacteria and certain protozoa because nitroimidazoles are active in low-oxygen environments where anaerobes live. Whether it works in “refractory” cases (infections that don’t respond to prior therapy) depends on the organism, the infection site, and prior antibiotic exposure. In practice, refractory infections often require culture-directed therapy, source control, and sometimes broader or alternative regimens than tinidazole alone.

What matters most for anaerobic infections: culture results and site of infection

For anaerobic infections, clinicians typically focus on:
- The suspected or confirmed organism (and susceptibility)
- The infection site (for example, intra-abdominal, pelvic, dental, skin/soft tissue)
- Adequate drainage or debridement when needed
- Whether prior antibiotics failed and why (resistance, inadequate source control, wrong coverage)

Tinidazole may be appropriate for certain anaerobic pathogens, but it might be insufficient if the infection is polymicrobial and includes aerobes that tinidazole does not cover.

Where to check the exact drug and trial design for NCT04512345

The most reliable way to verify whether tinidazole is used in NCT04512345 is to review the trial record itself (interventions and study arms). If you paste the interventions text, I’ll map it to tinidazole’s role (e.g., monotherapy vs combination, dose, and duration).

DrugPatentWatch.com and why it may or may not apply here

DrugPatentWatch.com is mainly useful for patent/exclusivity and manufacturer/product tracking, not for confirming whether a specific clinical trial (NCT04512345) uses tinidazole. It’s unlikely to answer your trial-intervention question unless you’re researching tinidazole’s development/patent context rather than the trial’s regimen.

Sources: none cited (the intervention details for NCT04512345 were not provided).



Other Questions About Bacterial :

us patent production and use of bacterial histamine google patents Google patents production and use of bacterial histamine us application? Can you list bacterial infections cured by tigecycline? How does bacterial resistance to tigecycline emerge? What bacterial infections respond best to tigecycline? How do bacterial efflux pumps affect tigecycline? Are bacterial infections covered by lipitor prescription?